Atara Biotherapeutics (ATRA) Interest & Investment Income (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Interest & Investment Income came in at -$1000.0 in Q1 2026, up 87.5% YoY from -$533.33 in Q1 2025, and little changed on a QoQ basis from -$1000.0 in Q4 2025.
Atara Biotherapeutics (ATRA) Interest & Investment Income (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Interest & Investment Income data on file, last reported at -$1000.0 in Q1 2026.
- Quarterly Interest & Investment Income rose 87.5% year-over-year to -$1000.0 in Q1 2026, while the trailing twelve-month figure through Dec 2025 was -$7000.0 (down 103.3% YoY) and the FY2025 annual result came in at -$7000.0, down 103.3% from the prior year.
- Interest & Investment Income held at -$1000.0 in Q1 2026, from -$1000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $892000.0 in Q4 2022 to a low of -$1.5 million in Q1 2022.
- A 5-year average of $23000.0 and a median of $19000.0 in 2024 frame the typical range for Interest & Investment Income.
- The widest YoY moves for Interest & Investment Income: up 327.55% in 2022, down 1028.89% in 2022.
- Tracing ATRA's Interest & Investment Income over 5 years: stood at $892000.0 in 2022, then tumbled by 58.86% to $367000.0 in 2023, then plunged by 103.81% to -$14000.0 in 2024, then surged by 92.86% to -$1000.0 in 2025, then changed by 0.0% to -$1000.0 in 2026.
- The last three Interest & Investment Income figures came in at -$1000.0 (Q1 2026), -$1000.0 (Q4 2025), and $2000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 | -2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,000.00 |
| Mar 31, 2026 | -1,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Mar 31, 2025 | -8,000.00 |
| Dec 31, 2024 | -14,000.00 |
| Sep 30, 2024 | 36,000.00 |
| Jun 30, 2024 | 41,000.00 |
| Mar 31, 2024 | 149,000.00 |
| Dec 31, 2023 | 367,000.00 |
| Sep 30, 2023 | 362,000.00 |
| Jun 30, 2023 | 304,000.00 |
| Mar 31, 2023 | 830,000.00 |
| Dec 31, 2022 | 892,000.00 |
| Sep 30, 2022 | -341,000.00 |
| Jun 30, 2022 | -726,000.00 |
| Mar 31, 2022 | -1.52 Mn |
| Dec 31, 2021 | -392,000.00 |
| Sep 30, 2021 | -38,000.00 |
| Jun 30, 2021 | -99,000.00 |